# Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

> **NCT01366144** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 94 (actual)

## Conditions studied

- Breast Carcinoma
- Carcinoma of Unknown Primary
- Endometrial Carcinoma
- Esophageal Carcinoma
- Liver Failure
- Lung Carcinoma
- Malignant Head and Neck Neoplasm
- Malignant Testicular Neoplasm
- Melanoma
- Metastatic Malignant Solid Neoplasm
- Ovarian Carcinoma
- Renal Failure
- Unresectable Malignant Neoplasm
- Urothelial Carcinoma

## Interventions

- **DRUG:** Carboplatin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **OTHER:** Pharmacological Study
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01366144
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-06-20
- **Primary completion:** 2017-11-10
- **Final completion:** 2027-03-03
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01366144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01366144, "Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01366144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*